Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWN study of oral granisetron plus dexamethasone for crizotinib-induced nausea and vomiting
jRCTs031180378Completed
- Sponsor
- Pfizer
- Start
- Sep 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of granisetron, dexamethasone and crizotinib in Nausea and Vomiting, sponsored by Pfizer. Primary endpoint: Complete response rate of control vomiting within 120 hours from start of crizotinib. Started Sep 2015; status: completed.
02
Drugs
granisetrondexamethasonecrizotinib
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on jRCTs031180378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180378.